octocog alfa

Octocog alfa is a recombinant protein that functions as a replacement therapy for patients with haemophilia A. It is a full-length recombinant version of human coagulation factor VIII produced using recombinant DNA technology in mammalian cells (such as Chinese hamster ovary or baby hamster kidney cells)[2][4][8]. Octocog alfa binds to endogenous von Willebrand Factor in the circulation; once activated, it acts as a cofactor for activated Factor IX to accelerate the conversion of Factor X to its active form. This cascade leads to thrombin generation and ultimately fibrin clot formation[1][2][5]. The drug is indicated for the prevention and treatment of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management[5][7]. It does not contain von Willebrand Factor itself[8].

Brand names

AdvateKovaltryIblias

Other names

recombinant factor VIIIrFVIIIhuman coagulation factor VIII (rDNA)full length recombinant human coagulation factor VIII